Linagliptin is a class drug for the treatment of type 2 diabetes mellitus that can promote the release of insulin from pancreatic islet β-cells and inhibit the secretion of glucagon by pancreatic α-cells. This evidence concerns the gene INS and type 2 diabetes mellitus.